Literature DB >> 10901301

The interaction of chalcones with tubulin.

N J Lawrence1, A T McGown, S Ducki, J A Hadfield.   

Abstract

The chalcone 3,4,3',4',5'-pentamethoxychalcone is a potent cytotoxic agent. A series of chalcones and (E)-4-(4'-hydroxyphenyl)but-3-en-2-one were prepared and assessed for their ability to inhibit cell growth in vitro. The cytotoxicity correlates with their ability to bind to tubulin as measured by immunofluorescence, cell cycle analysis and disruption of microtubule assembly. Some of the chalcones were shown to bind to the type II oestrogen receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901301

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  15 in total

1.  Dietary chalcones with chemopreventive and chemotherapeutic potential.

Authors:  Barbora Orlikova; Deniz Tasdemir; Frantisek Golais; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2011-02-04       Impact factor: 5.523

Review 2.  Chalcone: A Privileged Structure in Medicinal Chemistry.

Authors:  Chunlin Zhuang; Wen Zhang; Chunquan Sheng; Wannian Zhang; Chengguo Xing; Zhenyuan Miao
Journal:  Chem Rev       Date:  2017-05-10       Impact factor: 60.622

Review 3.  Drugs that target dynamic microtubules: a new molecular perspective.

Authors:  Richard A Stanton; Kim M Gernert; James H Nettles; Ritu Aneja
Journal:  Med Res Rev       Date:  2011-03-04       Impact factor: 12.944

4.  Effect of selected dimethylaminochalcones on some mitochondrial activities.

Authors:  Janka Vašková; Renáta Reisch; Ladislav Vaško; Martina Poškrobová; Ivan Kron; Juraj Guzy; Pál Perjési
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-04-19       Impact factor: 2.416

5.  EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.

Authors:  Shala L Thomas; Diansheng Zhong; Wei Zhou; Sanna Malik; Dennis Liotta; James P Snyder; Ernest Hamel; Paraskevi Giannakakou
Journal:  Cell Cycle       Date:  2008-06-09       Impact factor: 4.534

6.  Hybrid alpha-bromoacryloylamido chalcones. Design, synthesis and biological evaluation.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Dora Carrion; Olga Cruz-Lopez; Carlota Lopez Cara; Jan Balzarini; Ernest Hamel; Alessandro Canella; Enrica Fabbri; Roberto Gambari; Giuseppe Basso; Giampietro Viola
Journal:  Bioorg Med Chem Lett       Date:  2009-02-12       Impact factor: 2.823

7.  Quantitative Proteomic Profiling Reveals Key Pathways in the Anticancer Action of Methoxychalcone Derivatives in Triple Negative Breast Cancer.

Authors:  Catherine C Going; Dhanir Tailor; Vineet Kumar; Alisha M Birk; Mallesh Pandrala; Meghan A Rice; Tanya Stoyanova; Sanjay Malhotra; Sharon J Pitteri
Journal:  J Proteome Res       Date:  2018-09-20       Impact factor: 4.466

8.  Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse.

Authors:  S Sale; R G Tunstall; K C Ruparelia; P C Butler; G A Potter; W P Steward; A J Gescher
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

9.  Natural chalcones as dual inhibitors of HDACs and NF-κB.

Authors:  B Orlikova; M Schnekenburger; M Zloh; F Golais; M Diederich; D Tasdemir
Journal:  Oncol Rep       Date:  2012-06-15       Impact factor: 3.906

10.  Chalcone-imidazolone conjugates induce apoptosis through DNA damage pathway by affecting telomeres.

Authors:  M Janaki Ramaiah; Sncvl Pushpavalli; G Rama Krishna; Pranjal Sarma; Debasmita Mukhopadhyay; Ahmed Kamal; Utpal Bhadra; Manika Pal Bhadra
Journal:  Cancer Cell Int       Date:  2011-04-25       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.